NASDAQ:CERS Cerus (CERS) Stock Price, News & Analysis $1.50 -0.06 (-3.85%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$1.53 +0.03 (+2.00%) As of 07/3/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cerus Stock (NASDAQ:CERS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cerus alerts:Sign Up Key Stats Today's Range$1.50▼$1.5750-Day Range$1.23▼$1.5652-Week Range$1.12▼$2.54Volume388,973 shsAverage Volume1.33 million shsMarket Capitalization$286.74 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingBuy Company Overview Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California. Read More Cerus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreCERS MarketRank™: Cerus scored higher than 69% of companies evaluated by MarketBeat, and ranked 1135th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCerus has received no research coverage in the past 90 days.Read more about Cerus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.08) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 4.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cerus' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.72% of the float of Cerus has been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Cerus has recently decreased by 25.66%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.72% of the float of Cerus has been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Cerus has recently decreased by 25.66%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.49 News SentimentCerus has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cerus this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for CERS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Cerus to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of Cerus is held by insiders.Percentage Held by Institutions78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cerus' insider trading history. Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address CERS Stock News HeadlinesCerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update - Seeking AlphaJuly 4 at 3:17 AM | seekingalpha.comCerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application UpdateJuly 2 at 9:06 AM | businesswire.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.July 4 at 2:00 AM | Timothy Sykes (Ad)Cerus (NASDAQ:CERS) shareholders have endured a 80% loss from investing in the stock five years agoJune 24, 2025 | finance.yahoo.comCerus Corporation Celebrates World Blood Donor Day 2025June 13, 2025 | finance.yahoo.comCerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025June 3, 2025 | businesswire.comCerus to present new INTERCEPT Blood System data at ISBT CongressMay 30, 2025 | investing.comCerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in MilanMay 29, 2025 | businesswire.comSee More Headlines CERS Stock Analysis - Frequently Asked Questions How have CERS shares performed this year? Cerus' stock was trading at $1.54 at the beginning of 2025. Since then, CERS stock has decreased by 2.6% and is now trading at $1.50. How were Cerus' earnings last quarter? Cerus Corporation (NASDAQ:CERS) announced its earnings results on Thursday, May, 1st. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The biotechnology company had revenue of $43.24 million for the quarter, compared to analyst estimates of $47.44 million. Cerus had a negative trailing twelve-month return on equity of 34.81% and a negative net margin of 10.23%. Read the conference call transcript. How do I buy shares of Cerus? Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerus investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/01/2025Today7/04/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:CERS CIK1020214 Webwww.cerus.com Phone(925) 288-6000Fax925-288-6001Employees290Year Founded1991Price Target and Rating Average Stock Price Target$3.50 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside+133.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.92 million Net Margins-10.23% Pretax Margin-10.15% Return on Equity-34.81% Return on Assets-9.68% Debt Debt-to-Equity Ratio1.15 Current Ratio2.32 Quick Ratio1.63 Sales & Book Value Annual Sales$185.14 million Price / Sales1.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book4.84Miscellaneous Outstanding Shares191,160,000Free Float180,455,000Market Cap$286.74 million OptionableOptionable Beta1.56 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CERS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerus Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.